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HIV in Women
Brief Overview
The most recent AIDS statistics
have put the epidemic into chilling
perspective. HIV infection is now the
second leading cause of death in young
men in the United States. HIV is the 3rd
leading cause of mortality in young
minority women, more deadly than
suicide and homicide.
In the second decade of the
AIDS epidemic the new cases of AIDS
reported in 1992 among women have
increased 9.8%, compared to 2.5% for
men. .For the first time, more women
were infected through sexual contact than
I.V . drug use .
The greatest growth in new cases
has been among minority women, who
make up 19,544 of the 36,690 cases of
AIDS reported through June 1993. Only
cancer and heart disease outrank HIV
infection in mortality of young black
women, whereas AIDS is the ninth
leading cause of death in white women.
Newest CDC data confirms that
the epidemic is spreading most rapidly
among teens, especially girls. In 1993,
15% of U.S. cases of AIDS were women.
Maine statistics for June 1994 show that
8% of recently reported AIDS cases were
women.
Diagnosis of HIV in Women
The natural history of HIV
disease is similar in men and women . A
primary HIV syndrome ("flu-like" ,
"mono-like") may occur within 1-2
months of infection, to be followed by an
asymptomatic phase that usually persists
for years. As in men, early symptoms of
immune decline
may
include
dermatologic
disease
(worsening
seborrheic dermatitis, psoriasis, warts,
shingles, etc .) and, later on, thrush . In
addition, women with HIV may develop
chronic or recurrent monilial vaginitis.
Herpes genitalis and pelvic inflammatory
disease may become protracted and

difficult to treat. Unlike men , Kaposi's
sarcoma, however, has rarely been
reported in women.
To diagnose HIV in women,
physicians should include a sexual history
as part of their medical evaluation, be
alert to HIV -related symptoms, and be
able to facilitate HIV testing when
appropriate .
Management of HIV Disease in Women
Although most studies of HIV
disease and its treatment were based on
men, recent work suggests a similar
disease course and treatment response in
men and women. One very important
observation in women with HIV is the
increased incidence of cervical dysplasia
and carcinoma. Up to 50% of women
with HIV disease may have cervical
dysplasia, with the highest rates occurring
in women with lower CD4 counts. PAP
tests are recommended on an every 6
month basis in women with later stages
of HIV . Although the sensitivity of PAP
tests for dysplasia in women with HIV
has been questioned, a report at the recent
Yokohama International Conference
showed similar sensitivity of colposcopy
and PAP screening. However, when PAP
tests are abnormal, colposcopy should be
done to further evaluate the condition,
and may be necessary for subsequent
follow-up . Despite the high evidence of
dysplasia , invasive cervical carcinoma is
rare.
Prevention
Routine examination offers an
important opportunity for discussion of
sexually transmitted diseases and their
prevention.
The value of barrier
contraceptives and topical spermicides in
the prevention of herpes, chlamydia, and
HIV should be reinforced in women who
are at risk.

Mother to Child
Transmission of HIV
Decreased by AZT
Treatment
Transmission of HIV infection
from an HIV infected woman to her child
may occur in utero , during delivery , or
during postpartum breast feeding.
Previous studies have revealed a range of
transmission risk (10% to 40%), with the
highest risk occurring in women with late
stage HIV disease , or in developing
countries.
The results of a new study
(ACTG 076) of the effect of AZT on
vertical transmission of HIV
were
recently
released .
This study
demonstrated a 2/3 reduction in mother to
child transmission of HIV in the AZT
treated cohort.
This study included
women 14 - 34 weeks pregnant who had
not previously been treated with AZT .
The protocol involved AZT treatment of
the mother (500mg/d) until labor, then
initiation of IV AZT (2mg kg} until
childbirth. Following this, infants were
treated with AZT for 6 weeks .
No
adverse effects of this regimen were
noted in pregnant women or in their
babies, with the exception of a transient
anemia.
As a result of this study, the
FDA approved the use of AZT in HIV
positive pregnant women . Additionally,
the U.S . Public Health Service issued
guidelines (see insert) that incorponte the
uncertainties regarding the effectiveness
of these treatments when women have
later disease, prior history of AZT use , or
later stage pregnancy .
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Summary of National
Trials Specific To
women
Natural History Trials
A large scale study of the natural
history of HIV disease in women. funded
by the federal Centers for Disease Control
and Prevention in Atlanta, and called the
HIV Epidemiology Research Study
(HERS), is being conducted at 4 sites
across the country. Now in its first year
of accepting patients, the 5 year study is
enrolling a diverse group of 200 HIVpositive women and 100 high-risk women
at each site. Most of the HIV-positive
women will be asymptomatic and have
CD4 counts above 200.
A companion study, called the
Women's Interagency HIV Study (WIHS),
is being sponsored by the National
Institute of Allergy and Infectious
Diseases in Bethesda, MD. Like HERS,
WIHS will focus on identifying clinical
signs of HIV in women.
Both studies will try to identify
factors that affect the progression of the
disease in women. They will focus on
gynecological issues, but also measure
survival, psycho-social issues, access to
health care, and quality of life.
Other Significant Studies:
Begun in 1990 the Heterosexual
AIDS Transmission Study (HATS), has
investigated risk factors tied to
heterosexual transmission of HIV in
women, particularly the unexplained
higher risk among female cocaine users.
Preliminary analysis has shown
that female cocaine users have similar
knowledge and behaviors toward HIV as
non-cocaine users. The difference is that
cocaine users have more sexual partners
and more cases of other co-existing
STDs.
An NIAID-supported study is
comparing women's diagnosis and
survival compared to men's. Findings
indicate that women whose infections are
detected early survive as long as men and
respond to treatment similar to men.
Two studies within the AIDS
Clinical Trials Group are looking at
incidence of cervical dysplasia in women.
The focus of one of the studies is
comparing vaginal 5 Fluorouracil (5-FU)
therapy to standard therapy for preventing
recurrence of cervical dysplasia.
The Women and Infants
Transmission Study (WITS), begun in

1989, continues to look at the natural
history of HIV in pregnant women. A
second study on women and infants is
underway at the University of Medicine
and Dentistry in New Jersey, and includes
the effects of illegal drugs on pregnancies
in HIV - positive women.
Two early clinical trials
sponsored by NIAID are enrolling women
of childbearing age for two experimental
vaccines. A third candidate vaccine trial
is planned for pregnant women this fall.

Evidence continues to mount that
measures of viral load may predict the
clinical course of HIV. New sensitive
techniques that measure viral DNA or
RNA in serum or peripheral blood cells
may prove useful in determining
responses to anti-retroviral agents,
allowing clinicians to monitor course and
adjust therapy.
Although these
techniques are not in routine use,
preliminary studies suggest that they may
play a major role in the near future.

News Briefs from
Yokohama

3.
Combinations of Antiretroviral
Therapy Show Promise. Although the
results of several large trials of
combination anti-retroviral therapy are
not yet available, combination regimens
continue to show promise in pilot studies.
The addition of protease inhibitors,
which prevent viral assembly in HIV infected cells, may be beneficial,
particularly when used in combination
with reverse transcriptase inhibitors.
Several protease inhibitors are now
entering phase III trials.

In addition to the new
information on the benefits of AZT use in
seropositive pregnant women, the
following observations from the I 0th
International Conference on AIDS may be
of particular interest to clinicians:
I. Acyclovir appears to have a role as
adjunctive therapy in HIV disease.
Replication of Herpes viruses (HSV,
CMV, EBV, etc.) may activate coexisting HIV infection.
Therefore,
acyclovir, which inhibits replication of
some herpes viruses, might be expected
to have an indirect impact on HIV
disease in these patients. Previous studies
have suggested that the adjunctive use of
high dose acyclovir (3-4 g/day) with AZT
improves CD4 cell counts and/or survival
in HIV infected persons.
The
results of the Multicenter AIDS
Cohort Trial were presented in
Japan. This large observational
study demonstrated a survival
benefit in patients receiving daily
acyclovir (600-800 mg/day) in
addition of AZT. The benefit was
not limited to patients with a
history of active herpes infections,
though the vast majority of patients
in this study were likely to be
infected with HSV or CMV. The
benefit of acyclovir was most
apparent in patients with lower
CD4 counts or AIDS defining
illness. Although these studies are
not conclusive, many clinicians are
now adding acyclovir (600-800
mg/d) to other treatment regimens
in HIV infected patients with later
stages of disease.
2.

New Measures of Viral Load

(PCR for HIV RNA • . branched

DNA tests) Have Predictive Value
in Determining the Course of HIV.

4.
Oral Gancyclovir Effective for
Prevention of and Suppression of CMV
Retinitis and Gastrointestinal mucosa!
Disease. Although not yet released by
the FDA, oral gancyclovir may prevent
50% of cases of CMV retinitis, and can
be effective in long term treatment of
CMV retinitis.

Active Treatment Arm of ACTG 076
Prepartum (mother)
Labor/Delivery (mother)
Postpartum (infant)

Zidovudine 100 mg po sx day
Zidovudine IV loading dose 2 mg/kg; continuous infusion
1 mg1kg1hour
Zidovudine syrup 2 mg/kg po 4x day for 6 weeks.

Management of GYN Infections in HIV+ Women
Reference Used: The Sanford Guide to HIV/AIDS Therapy July 1993-1994
Problem

Treatment

Vulvovaginal Candidiasis I Yeast Infection:
May be the I st symptom of HIV infection in women, 1/3 of
women with HIV develop chronic genital yeast infections.
Causes severe itching & burning, odor, and "cheesy" discharge.

Topical (Vaginal):
a. Miconazole nitrate 200 mg vag. tabs (I qd hs x 3 days) or
2% cream (5gm) qd hs x7 days
b. Clotrimazole 100 mg vag. tabs(2 qd hs x 3 days) or
I% cream (5 gm) qd hs x 7 days
Oral
a. Fluconazole 150 mg p.o. qd. x3 day s (Not an FDA -approved
indication)
b. Itraconazole 200 mg p.o. qd. x3 days (Not an FDA-approved
indication)
Suppressive Therapy
Fluconazole 50 mg po 3x/week or 200 mg po Ix/week is under
study .

Human Papillomavirus (HPV)
Associated with the development of anogenital warts which may
cause obstruction, abnormal pap smears, warts on the cervix , and
possibly cancer-causing tissue growth; strongly associated with
genital dysplasia . Cervical warts should not be treated until
results of pap smear are known ; avoid treating pregnant women.

Podofilox or 25% podophyllin in tincture of benzoin applied
topically (apply weekly x4)
Alternatives: cryotherapy with liquid nitrogen, electocautery.
Pap smears (q 6 months)
Colposcopy with cervical biopsy if pap is abnormal.

Pelvic Inflammatory DiseaseJPim
Possibly caused by sexually transmitted organisms and though to
be associated with chlamydia, with pelvic inflammation of the
upper genital tract; also common are collections of pus in the
fallopian tube or ovary . More common and more serious in
women with HIV .

Outpatient (temp <38, WBC < 11 ,000 , minimal evidence of
peritonitis, active bowel sounds, qd p.o. intake) :
a. Ceftriaxone 250 mg IM single dose plus doxycycline 100 mg
bid po xl4 days
b. Cefoxitin 2.0 gm IM single dose plus probenecid 1.0 gm.
concurrently plus doxycycline
c. Ofloxacin 400 mg po bid plus metronidazole (500 mg bid) or
clindamycin (450 mg q6h) for 14 days .
Hospitalized
a. Cefoxitin 2.0 gm q 6h IV plus doxycycline 0. 1 gm IV q 12
hr. x min. 4 days and afebrile x48 hrs.
b. Clindamycin 900 mg q. 8 hr. IV plus gentamicin (same time
frame). Follow with oral agent doxycycline) to complete
14 days.

Herpes Simplex Virus (HSV)
Chronic lesions on vulvar or vaginal walls

Mucocutaneous:
Acyclovir 200 mg po 5x/day x IO days
Suppression:
Acyclovir 400 mg p.o . bid indefinitely .

Summary of Clinical Situations and Recommendations for
Use of Zidovudine (AZT) to Reduce Perinatal HIV Transmission
Per U.S. Department of Health & Human Services. Recommendations of the U.S. Public Health Service Task Force on the use ofzidovudine to reduce perinatal transmis,ion
of human immunodeficiency virus. Morbidity and Mortality Weekly Report 43 (RR-I) August 5, 1994.
See Reverse Side for Protocol

Clinical Situation

Recommendation (See Reverse Side for ACTG Protocol 076)

Pregnant HIV-infected women with CD4+ Tlymphocyte counts > or= to 200 who are at
14 - 34 weeks of gestation and who have no
clinical indications for ZDV and no history of
extensive (>6 months) prior antiretroviral
therapy. (This represents the group studied in
ACTG Protocol 076)

The health care provider should recommend the full ACTG Protocol 076
regimen to all HIV-infected pregnant women in this category. This
recommendation should be presented to the pregnant woman in the
context of a risk-benefit discussion : a reduced risk of transmission can
be expected, but the long-term adverse consequences of the regimen are
not known . The decision about this regimen should be made by the
woman after discussion with her health care provider.

Pregnant HIV-infected women who are at >34
weeks of gestation, who have no history of
extensive (>6 months) prior antiretroviral
therapy, and who do not require ZDV for
their own health.

The health care provider should recommend the full ACTG Protocol 076
regimen in the context of a risk-benefit discussion with the pregnant
woman. The woman should be informed that ZDV therapy may be less
effective than that observed in the ACTG Protocol 076 , because the
regimen is being initiated in the third trimester.

Pregnant HIV-infected women with CD4+ Tlymphocyte counts <200 who are at 14 - 34
weeks of gestation, who have clinical
indications for ZDV, and who have no history
of extensive (>6 months) prior antiretroviral
therapy.

The health care provider should recommend initiation of antenatal ZDV
therapy to the woman for her own health benefit. The intrapartum and
neonatal components of the ACTG Protocol 076 regimen should be
recommended until further information becomes available. This
recommendation should be presented in the context of a risk benefit
discussion with the pregnant woman.

Pregnant HIV-infected women who have a
history of extensive (>6 months) ZDV
therapy and/or other antiretroviral therapy
before pregnancy.

Because data are insufficient to extrapolate the potential efficacy of the
ACTG Protocol 076 regimen for this population of women, the health
care provider should consider recommending the ACTG Protocol 076
regimen on a case-by-case basis after a discussion of the risks and
benefits with the pregnant woman . Issues to be discussed include her
clinical and immunologic stability on ZDV therapy, the likelihood she is
infected with a ZDV-resistant HIV strain and, if relevant, the reasons for
her current use of an alternative antiretroviral agent (e.g., lack of
response to or intolerance of ZDV therapy). Consultation with experts in
HIV infection may be warranted. The health care provider should make
the ACTG Protocol 076 regimen available to the woman. Although its
effectiveness may vary depending on her clinical status.

Pregnant HIV-infected women who have not
received antepartum antiretroviral therapy and
who are in labor.

For women with HIV infection who are in labor and who have not
received the antepartum regimen component of the ACTG Protocol 076
regimen (either because of lack of prenatal care or because they did not
wish to receive antepartum therapy), the health care provider should
discuss the benefits and potential risks of the intrapartum and neonatal
components of the ACTG Protocol 076 regimen and offer ZDV therapy
when the clinical situation permits .

Infants who are born to HIV-infected women
who have received no intrapartum ZDV
therapy.

If the clinical situation permits and if ZDV therapy can be initiated
within 24 hours of birth, the health care provider should offer the ACTG
Protocol 076 postpartum component of 6 weeks of neonatal ZDV
therapy for the infant in the context of a risk-benefit discussion with the
mother. Data from animal prophylaxis studies indicate that, if ZDV is
administered, therapy should be initiated as soon as possible (within
hours) after delivery. If therapy cannot begin until the infant is >24
hours of age and the mother did not receive therapy during labor, no data
supports offering therapy to the infant.

The
Patient's
Perspective
I tested positive for HIV in April
of 1992. I received the news one afternoon,
when I was home alone . What I heard was
a death sentence. I was going to die . I am
a nurse and had a basic knowledge about
HIV. That knowledge went right out the
window and I lived in a world of pure
emotions; mostly fear and panic . I never
dreamed that I would really test positive ,
after all I only was tested to humor someone
else. I wasn't aware of any other women
who had HIV . I basically viewed it as a
"gay mans disease''. I certainly couldn't tell
anyone . I had seen and read the news
stories about families who had been burned
out of their houses and people who had lost
their jobs, families and friends . What if that
happened to me? What would people think?
Does this mean that I am bad? Our society
has placed an inordinate judgmental burden
on people living with HIV . You have to
have done something wrong to get this virus.
If I had become infected because of a blood
transfusion or as a consequence of being
raped, then I am viewed as a poor innocent
victim. However, if I acquired this virus as
a result of unprotected sex or the use of IV
drugs, then I am a "bad girl" , and the
implication is that I deserved it. I've heard
numerous stories from other women who
were misdiagnosed or undiagnosed because
their physician thought that they couldn't
possibly have HIV - they were "nice girls".
The burden and stress of living with
such a huge secret finally outweighed my
fears . I started to think about how I could
disclose and to whom. I needed support.
Could I get it and still protect myself, both
physically and emotionally? I was lucky. I
only lost my job and a few friends. I
eventually decided to speak publicly . As a
result I receive anonymous phone calls and
letters telling me to move out of my
neighborhood ; they don't want "my kind"
here.
It was very difficult for me to look to the
various AIDS service organizations for help
and support. I viewed them as being places
that were set up for men and was very
suspicious of their ability to be open to
dealing with a woman. I eventually joined
a support group for women and over time
met about IO other women from my area.
My support group became very important to

me. It is a group of women who have
experienced loss and yet still have hope .
Many of them have been in this place before
me and are able to tolerate my restlessness,
my terror, my despair, my rage . It is a place
where I can experience feelings that would
be burdensome for others. Yet it is a double
edged sword; for each person that I meet
who can understand and support me is also
someone whom I may watch get sick and
die . And that's happened many times.
There are many more women, (over 40),
who live in my area that are HIV positive ,
who live in fear and are unable to go to a
support group . Many do not feel safe
enough to receive AIDS related mail or
newsletters at their homes . They are afraid
for their jobs, that their children may be
ostracized, that their families will place
blame, or for their physical safety. Having
lived with my own secret for a limited
period of time , I know how difficult that is.
Because I am an information
oriented person and have access to a medical
center library, I am constantly looking for
information on Women and HIV. At first , I
didn't find much. Most of the medical
information was based on studies that were
done on men . Women seemed to be either
ignored or viewed as vessels or vectors of
this virus. If it was acknowledged that
women got HIV , why weren't there any
studies about women?
There was
information about women transmitting it to
their babies, but very little about women
themselves. All of the drug studies were
done on men. How does anyone know how
my hormone level s may or may not react
with these drugs. Does the different fat
content of my body have any effect? Is my
reproductive system affected by HIV? If so ,
how? It scares me and makes me very
angry about how little is known . It wasn't
until last year that the first large natural
history study was started on women and the
CDC changed it's definition of AIDS to
include a women specific indicator. The
uncertainty of living with this virus is like
carrying a 20 lb bag of garbage on your
shoulder and not knowing when it's going to
break. I have enough to think about and to
deal with, without wondering or worrying
what's different about me because I'm a
woman.

The decision to find regular medical
care was huge. Everyone makes mistakes
and no one knows everything: secretaries
make
typos,
businesses
make
bad
investments - but this is my life. Would I
die an early death because I was not
competent enough to discern and judge the
incompetency of my doctor? It was over 6
months after my diagnosis before I went to
a doctor, (after I finally found one who
knew something about HIV and who would
see me) . My primary physician is my
consultant.
I respect his opinion and
judgement and usually do take his advice to
heart, but in the end it's my body ; I have to
"run the show". However I find myself in
the position of having to educate other
physicians. I resent the fact that I need to
remind my GYN physician that I need to see
her every 6 months for a pap smear or that
she assumes because of my HIV status that
I'm not sexually active and don't need birth
control. It's not my job to stay informed
enough so that I can inform her. I'm lucky
because I have access to information that
most women don't so that I can stay
informed; and I have the skills to speak up,
to question, and to talk back.
What do I need from a physician? I need
your educated professional advice , not your
personal judgments. What I need is personal
medical care , not just medicine.
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World AIDS Cases
2,500,000*
us AIDS Cases
361,509
us AIDS Deaths
220,871
Total US cases and deaths reported through
12/31/93

HIV & Women in the U.S.
AIDS: 36,690
HIV : 80,000140,000
Median Age for AIDS:
30-34
Percentage of U.S. AIDS Cases: 15%

Maine AIDS Cases
530
Maine AIDS Deaths
279
Total Maine cases and deaths reported through 06/30/94
*Estimated

Educational Sessions
October 16, 1994
"Women's Health Care Issues Across the Life Span" Sponsored by USM at the Ramada Inn. Port.
October 19-21, 1994 "CareandManagementoftheHIVIAIDSPatient:ACourseforPrimaryCareProuiders'Sponsored
by the New England AIDS education and Training Center. University of Mass. Medical Center
October 24, 1994
"HIV Disease - Nursing Implications" St. Josephs College
October 26, 1994
"Primary Care Management of HIV" Univ. of Me. Orono
October 27, 1994
"HIV Update" Wentworth Douglas Hospital, Dover, N .H.
November l, 1994
""Yokohama Update" Mercy Hospital - ANAC Meeting
November 2, 1994 "Community, Advocacy, & Family Connections: Contemporary Practice with HIV/AIDS'
Sponsored by USM & ACS at the Holiday Inn by the Bay, Portland .
November 14, 1994 "HIV Update" PenBay Medical Center, Rockport Me.
November 28, 1994 "Psychosocial Issues & HIV" at University of New England
November 30, 1994 "HIV Update" The AIDS Project, Portland, Maine
December 11 , I 994 "Women and HIV" location TBA, Bangor Maine
January 19, 1995
"Outpatient Management of HIV" Grand Rounds, Mid Maine Medical Ctr. Waterville.Me.
February 15, 1995
"Outpatient Management of HIV" Grand Rounds, Franklin Mem . Hosp., Farmington. Me.

For more information regarding the above educational sessions, please call the ACS at 871-2099.
If you are providing an HIV/AIDS related Educational Session, please let us know at (800)871-2701.

Maine Medical Center
AIDS Consultation Service
22 Bramhall Street
Portland Maine 04102
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